A clinical case of treatment HER-2 blockers cancer therapy-related cardiac dysfunction

This clinical case about of left ventricular systolic dysfunction with chronic heart failure associated with targeted therapy with trastuzumab and pertuzumab in a patient suffering from HER-2 positive breast cancer. The exogenous phosphocreatine (“Neoton”) was added to the standard treatment of chronic heart failure with sacubitril/valsartan, bisoprolol, spironolactone or empagliflozin. It made possible to achieve an additional increase in the left ventricular ejection fraction and preventing interruption of targeted therapy and continue it as before.